62 results about "Arachidonic acid" patented technology

The invention belongs to the technical field of animal molecular markers, and particularly relates to an SNP molecular marker for beef cattle flavor character breeding and application of the SNP molecular marker. The invention proposes that genotype polymorphism of 84181318bp and 84181699bp on chromosome 3 of an international bovine reference genome AR-UCD1.2 version is related to the character of the content of the beef arachidonic acid for the first time, the genotype polymorphism can be used for evaluating the content of the beef arachidonic acid, and beef cattle with specific genotypes at the two sites has relatively high content of the beef arachidonic acid. The site can be used as a molecular marker for evaluating the content of the arachidonic acid in the beef cattle, early prediction and auxiliary screening of beef cattle individuals with excellent meat quality and flavor characters, and a theoretical basis and a technical support are provided for breeding of the beef cattle with high content of the arachidonic acid in the beef cattle.

Disclosed herein are compositions and methods for controlling chronic inflammation in a patient. The compositions and methods employ D6-arachidonic acid or an ester thereof (D6-AA) as an anti-inflammatory agent that provides for significant reduction in inflammatory processes. In addition. The compositions of deuterated arachidonic acid or ester thereof comprise, on average, at least about 80% of the hydrogen atoms at each of the bis-allylic sites having been replaced by deuterium atoms and, on average, no more than about 30% of the hydrogen atoms at the mono-allylic sites having been replaced by deuterium atoms.

The invention discloses a compound grease feed additive for improving breeding quality of channa maculata and application. The method comprises the following steps: (1) preparing experimental feed; the method comprises the following steps: respectively preparing an experimental group ARA 1.5 added with 1.5% of arachidonic acid and an experimental group ARA + PC added with 1.5% of arachidonic acid and 1.5% of phosphatidylcholine; (2) feeding; (3) after the culture experiment is finished, treating and detecting the channa maculata; (4) carrying out an artificial propagation test; (5) carrying out ovarian steroid synthesis related gene expression detection; and (6) carrying out data statistical analysis. By adding arachidonic acid (ARA) and phosphatidylcholine (PC) into the feed, the breeding performance of channa maculata and the quality of fry are improved, and the feed has very important significance for improving the aquatic product efficiency of high-quality fry of channa maculata in aquaculture.

The application relates to a probiotic / arachidonic acid composite microcapsule and a preparation method thereof, and belongs to the technical field of microcapsule preparation, and the specific scheme is as follows: a probiotic / arachidonic acid composite microcapsule comprises wall material and core material, the core material is wrapped in the wall material, the wall material comprises sodium alginate and sodium carboxymethyl cellulose, the core material comprises arachidonic acid and probiotics, the arachidonic acid is dissolved in an oily carrier and forms a water-in-oil emulsion with a probiotic bacterial suspension, the sodium carboxymethyl cellulose wraps water-in-oil emulsion droplets, and the sodium alginate reacts with the sodium carboxymethyl cellulose to generate a gel film microcapsule wall material. The method for preparing the probiotic / arachidonic acid composite microcapsule provided by the application is simple to operate, the microfluidic chip is simple to prepare and low in cost, has a high embedding rate, the particle size of the microcapsule is controllable, and the biological activity is good.

The application belongs to the technical field of molecular biology, and particularly relates to metabolic markers for evaluating the prognosis of patients with hypertrophic cardiomyopathy and application thereof. The application determines that one or more of 3-hydroxyrilotene, asparagine-lysine, cyclohexylamine, arachidonic acid, aconitic acid, propionyl carnitine, ceramide, tryptophan, 3-hydroxysebacic acid, traumatic acid, phosphatidylcholine, alanine-proline, lysophosphatidylcholine, taurine and S-garlicin cysteine are related to the prognosis of hypertrophic cardiomyopathy, can evaluate the prognosis of patients with hypertrophic cardiomyopathy after undergoing muscle resection of interventricular septum, and shows accurate judgment on all-cause death or rehospitalization, cardiovascular events and postoperative new-onset arrhythmia. Finally, all the prognostic biomarkers are reproduced in an independent cohort, which is helpful for postoperative risk evaluation of patients with hypertrophic cardiomyopathy, has high specificity and high sensitivity.

The application belongs to the technical field of biotechnology, and particularly relates to a kind of snake venom polypeptide and application thereof.The snake venom polypeptide is polypeptide DACU-1, polypeptide DACU-2 or polypeptide DACU-3.The application provides a kind of new snake venom polypeptide, including three polypeptides, and the three polypeptides all have anti-platelet aggregation activity, and have the activity of inhibiting platelet aggregation under the stimulation of ADP, arachidonic acid, collagen, thrombin and other various activators, and have the potential to be developed into anti-platelet drugs, functional foods and health products.

The application discloses application of Fagopyrum cymosum root powder in preparation of products for improving egg quality or intestinal health of laying ducks, and belongs to the technical field of feed additives. The application provides application of Fagopyrum cymosum root powder in preparation of products for improving egg quality or intestinal health of laying ducks, and the Fagopyrum cymosum root powder can improve eggshell strength, yolk color and eggshell proportion, improve the content of aspartic acid, threonine, glutamic acid, glycine, cystine and leucine in yolk, improve the content of arachidonic acid and arachidonic acid in yolk, and reduce the content of saturated fatty acid in yolk; the Fagopyrum cymosum root powder can improve the activity of maltase in the mucous membrane of the jejunum of laying ducks, and can improve the diversity and abundance of intestinal flora of laying ducks. The application provides a new strategy for improving egg quality or intestinal health of laying ducks.

The invention discloses a composite elicitor for promoting taxus chinensis embryogenic stem cells to produce paclitaxel and application, and belongs to the technical field of biology. The compound elicitor consists of methyl jasmonate, indolebutyric acid and salicylic acid, and the working concentrations of the methyl jasmonate, the indolebutyric acid and the salicylic acid in a culture medium are respectively as follows: 50-800 mu mol / L of methyl jasmonate, 12.5-50 mu mol / L of indolebutyric acid and 0.1-0.5 mg / L of salicylic acid. Preferably, the jasmonic acid methyl ester is 200 [mu] mol / L, the indolebutyric acid is 25 [mu] mol / L, the salicylic acid is 0.5 mg / L, and 0.1-0.5 mg / L arachidonic acid can be selectively added. The composite elicitor is added in the early stage of the exponential growth phase of the taxus chinensis embryogenic stem cells, and the taxus chinensis embryogenic stem cells are continuously cultured for 5 days, so that the yield of paclitaxel reaches 27.52 mg / L and is 7.86 times that of blank control, and meanwhile, the maximum biomass is obtained. According to the invention, the synergistic interaction of the three elicitors is realized for the first time, the production period is remarkably shortened, a set of efficient and stable paclitaxel production system is established, and an innovative solution is provided for large-scale production of paclitaxel.

The invention discloses a preparation method of an arachidonic acid lipid nano drug delivery system, and relates to the technical field of biology, the lipid nano drug delivery system comprises the following components: (1) ionizable lipid; (2) arachidonic acid; (3) a conjugated lipid that inhibits particle aggregation of a non-cationic lipid or an ionizable lipid; (4) non-cationic lipids or non-ionizable lipids other than (3); (5) metal ions; (6) a nucleic acid drug; the lipid nano drug delivery system is formed by mixing and self-assembling at least the components (1) to (6). According to the novel preparation method of the lipid nano drug delivery system, cancer cells are specifically killed through lipid replacement and simultaneous use of nuclear nucleic acid drugs and metal ions, the treatment accuracy is improved, and the stability and the lysosome escape rate can be increased.

The invention belongs to the technical field of microorganisms, food science and medicine, and particularly relates to bifidobacterium longum subsp.infantis SZBLI1052 and application thereof. The invention discloses that the obvious synergistic anti-inflammatory effect exists between the specific strain B. longa subsp. Infantis SZBLI1052 and the arachidonic acid (ARA) for the first time, and the specific strain B. longa subsp. Infantis SZBLI1052 has the obvious synergistic anti-inflammatory effect on the arachidonic acid (ARA) and the arachidonic acid (ARA). Compared with the single use of SZBLI1052 or ARA, the combined use of SZBLI1052 and ARA shows a synergistic effect, so that the LPS-induced inflammatory response can be more effectively inhibited, and the protection effect on the intestinal barrier is enhanced. The invention also finds that the strain SZBLI1052 can specifically and obviously consume ARA, and can efficiently metabolize and convert ARA into a key metabolite lipoxin B4 (LXB4) with anti-inflammatory activity. The composition of the SZBLI1052 and the ARA is applied to the infant formula milk, and the synergistic anti-inflammatory effect of the composition is verified. The discovery of the invention lays a solid foundation for developing a new generation of functional infant formula food with synergistic anti-inflammatory characteristics, and has important application potential and industrialization value in the aspect of realizing precise immune nutrition intervention of newborns.

This invention relates generally to compositions and methods for preventing, reducing the occurrence of or treating a headache in a subject in need thereof. In particular, the present invention relates to methods for enhancing 2-arachydonyl glycerol (2AG) tone and reducing prostaglandin activity in a subject for purposes of preventing, reducing the occurrence of or treating a headache (e.g., a migraine headache) in a subject.

The application discloses a novel and powerful inhibitor of fatty acid amide hydrolase (FAAH), pyridinone compound (formula I) and therapeutic effect thereof in related diseases, and belongs to the technical field of biological medicine. The inhibitor can inhibit the biological activity of fatty acid amide hydrolase (FAAH), increase the physiological concentration of endogenous arachidonic acid ethanolamine, and play the roles of regulating immunity and resisting inflammation; for example, in inflammatory bowel disease, the inhibitor can significantly improve various pathological and physiological indexes of animals in an inflammatory bowel disease (IBD) model, slow down the progress of the disease, and be effectively used for treating multiple types of inflammatory bowel disease (IBD) including ulcerative colitis (UC) and Crohn's disease (CD).

The invention relates to a lipid nutritional composition, a product comprising the same and application of the lipid nutritional composition in preparation of a product for promoting structural development of neural stem cells. The lipid nutritional composition comprises: docosahexaenoic acid and / or a metabolic precursor thereof; arachidonic acid and / or a metabolic precursor thereof; and a population of phospholipids consisting of phosphatidylcholine (PC) and / or a metabolic precursor thereof, phosphatidylserine (PS) and / or a metabolic precursor thereof, phosphatidylethanolamine (PE) and / or a metabolic precursor thereof, phosphatidylinositol (PI) and / or a metabolic precursor thereof, and sphingomyelin (SM) and / or a metabolic precursor thereof; wherein the ratio of the molar equivalents of arachidonic acid to the molar equivalents of docosahexaenoic acid, ARA / DHA, is 1-2: 1; and the ratio of the total molar equivalents of the phospholipid population to the molar equivalents of docosahexaenoic acid, PHL / DHA, is 1-8: 1.

The invention relates to application of arachidonic acid (ARA) in preparation of a medicine for treating sleep disorder related spontaneous abortion. Peripheral blood lipid metabolism sequencing analysis finds that the ARA content in peripheral blood serum of a patient suffering from sleep disorder and repeated pregnancy loss is most obviously reduced compared with that of a patient suffering from normal sleep and normal pregnancy; an enzyme-linked immunosorbent assay test shows that the content of ARA in decidua stromal cells (DSCs) of a patient with sleep disorder and repeated pregnancy loss is remarkably reduced compared with that of a pregnant person with normal sleep; after the endometrial stromal cells (ESCs) are subjected to ARA treatment, the in-vitro decidualization level is increased; the ARA inhibitor can be used for inhibiting the in-vitro deciduation level of the ESCs; compared with a mouse with normal sleep, the content of ARA in peripheral blood and DSCs of a mouse with sleep disorder is remarkably reduced, decidua is poor, and the abortion rate is increased; supplementing ARA can improve decidua disorder and high abortion rate caused by sleep disorder. Therefore, a potential target and a new idea are provided for diagnosis and treatment of repeated pregnancy loss related to sleep disorder.

The invention provides an isoquinoline derivative with a novel structure, a pharmaceutically acceptable salt thereof, a preparation method of the isoquinoline derivative, a pharmaceutical composition containing the isoquinoline derivative and pharmaceutical application of the isoquinoline derivative, and belongs to the technical field of medicines. In-vitro experiments show that the isoquinoline derivative has significant inhibitory activity on arachidonic acid-induced platelet aggregation, and the antiplatelet activity of part of compounds is superior to that of aspirin. In a rat carotid artery thrombosis model induced by FeCl3, the isoquinoline derivative remarkably prolongs thrombosis time and reduces thrombus weight, and the in-vivo antithrombotic curative effect of the isoquinoline derivative is equivalent to that of aspirin and ticagrelor. A mouse tail bleeding model shows that the side effects of bleeding amount and bleeding time of the isoquinoline derivative are obviously lower than those of aspirin and ticagrelor. Therefore, the series of isoquinoline derivatives have the advantages of efficient antithrombotic effect and low bleeding risk, and have good application prospects in preparation of drugs for preventing and treating thrombotic diseases. In addition, the preparation method provided by the invention has the advantages of easily available raw materials, simple steps and strong operability, and the obtained target product has high quality and good efficiency.

The invention discloses an Anandamide composition, which comprises, by weight, 30-75 parts of Anandamide, 5-15 parts of Linolcoylethanolamide, 2-18 parts of Oleoylethanolamide. The Anandamide composition of the invention can achieve a good antidepressant effect.

The invention relates to an effect of limited uptake of arachidonic acid (AA) in preparation of a chemotherapy sensitizer, and particularly relates to an application of the arachidonic acid (AA) in preparation of the chemotherapy sensitizer. A large number of researches find that the AA content is extremely related to the colorectal cancer chemotherapy resistance, the high level of AA has negative correlation with the colorectal cancer chemotherapy sensitivity, the AA can be used for predicting the colorectal cancer chemotherapy tolerance and sensitivity degree, and early evaluation is provided for the relation of preoperative treatment of a patient. Meanwhile, AA uptake is limited, for example, AA transporter SLC27A4 is inhibited, an important function of colorectal cancer chemotherapy sensitization is achieved, correspondingly, the tolerance of a patient to colorectal cancer chemotherapy can be reduced by reducing the level of AA in a body, the chemotherapy treatment effect is improved, the survival rate of the patient is prolonged, and prognosis is improved. The invention provides sufficient scientific basis and theoretical basis for exploring new colorectal cancer diagnosis, prognosis judgment and treatment molecular targets and developing new targeted drugs, is helpful for better realizing accurate treatment, and has important social value and scientific significance.

The invention relates to milk powder for improving child anorexia and a preparation method thereof, which comprises the following steps: putting low-temperature soybean meal as a raw material into a tank, adding 9 times of water at the water temperature of 30-40 DEG C, stirring in the tank, feeding into a high-speed separator, separating soybean dregs, carrying out acid precipitation, separation, neutralization, sterilization and drying treatment on protein water, carrying out low-temperature superfine grinding on dried protein powder by using a superfine grinding machine, and packaging to obtain the milk powder for improving child anorexia. The preparation method comprises the following steps: uniformly mixing whey protein powder, fresh milk, fructo-oligosaccharide, galactooligosaccharide, milk mineral salt, compound trace elements and compound vitamins to obtain a mixed material liquid, and carrying out homogenization, high-pressure homogenization, sterilization, concentration and spray drying on the obtained mixed material liquid to obtain the milk powder. The milk powder, the soybean protein micro powder, the docosahexaenoic acid fish oil powder, the arachidonic acid grease and the composite probiotic powder are uniformly mixed to finally obtain the infant formula milk powder, and the milk powder obtained by the method is quick to dissolve, promotes digestion and has the effects of obviously improving food retention, constipation and anorexia.

The invention relates to nannochloropsis oculata SH2 as well as a screening method and application thereof, and belongs to the technical field of microorganisms. The nannochloropsis oculata SH2 is preserved in the China Center for Type Culture Collection on June 19, 2025, and the preservation number of the nannochloropsis oculata SH2 is CCTCC (China Center for Type Culture Collection) NO: 20251433. The nannochloropsis oculata SH2 disclosed by the invention is rich in long-chain polyunsaturated fatty acid, and can be used for simultaneously producing various high-value products such as EPA (eicosapentaenoic acid) and ARA (arachidonic acid), so that the comprehensive utilization value and economical efficiency of the SH2 are greatly improved, and a foundation is laid for developing compound nutrient products for different people.

The invention relates to a pharmaceutical composition of an extract of Agarophyton chilensis, with antiproliferative effect in prostate cancer, comprising(a) 0.1 to 90% of an oleoresin of Agarophyton chilensis, with the following major components: palmitic acid, arachidonic acid, oleic acid, stearic acid, meristic acid, linoleic acid; and(b) 10 to 99.9% excipients and formulation aids for different pharmaceutical forms.And its use to prepare a drug for the treatment or prevention of prostate cancer and other hyperproliferative states of prostate tissue cells.

The invention belongs to the technical field of grease production through microbial fermentation, and particularly relates to a fermentation production method of grease with high DHA (docosahexaenoic acid) or ARA (arachidonic acid) yield and high sn-2 proportion, which comprises the steps of strain activation, seed culture, basic fermentation inoculation (seed liquid is inoculated according to 8-12% (v / v) inoculum size in logarithmic phase), fermentation and fermentation. And adding compound amino acid compounded by valine, isoleucine and phenylalanine into the basic culture medium, fermenting for 24-48 hours, supplementing ammonia water-compound organic acid to regulate pH and metabolic flux, fermenting for 48 hours, 72 hours and 96 hours, and supplementing tricarboxylic acid cycle precursor substances to realize staged nutrition regulation. According to the method, the yield of DHA or ARA can be increased by 20% or above, the sn-2 site proportion is increased to 50% or above, the cost of the culture medium is reduced by 35% or above, the method is suitable for large-scale production, and high-quality DHA and ARA raw materials are provided for the fields of food, health care products and medicines.

The invention discloses an application of arachidonic acid as an interleukin 5 receptor antagonist, and belongs to the technical field of biological medicines.The application comprises the steps that an interleukin 5 receptor serves as a target, and drug molecules capable of being combined with the interleukin 5 receptor in an FDA drug library are screened in a high-throughput mode; according to the invention, arachidonic acid is used as an antagonist of interleukin-5 receptors, the antagonism efficiency of the arachidonic acid is verified at an in-vitro molecular level, a molecule capable of antagonizing interleukin-5 receptors is screened out, the concentration of the screened arachidonic acid reaching the same antagonism effect as benralizumab is 86.61 pg / ml, and the application prospect of the arachidonic acid as the interleukin-5 receptor antagonist is proved.

The invention relates to an antibacterial high-strength organic composite material and a preparation method thereof. The antibacterial high-strength organic composite material comprises the following components: polypropylene, polyvinyl alcohol, modified titanium dioxide, epoxidized soybean oil, carboxymethyl cellulose, a filler and an auxiliary agent. Wherein the modified titanium dioxide is obtained by firstly carrying out blending reaction on hydroxylated titanium dioxide and arachidonic acid and then carrying out blending reaction with styrene, butyl acrylate and methacrylic acid tannic acid. A long alkyl chain, a benzene ring, acrylate and tannic acid are introduced into the modified titanium dioxide; wherein the long alkyl chain can improve the dispersibility and mechanical properties, the benzene ring can further improve the mechanical properties, the acrylate can improve the compatibility of the components, and the tannic acid can improve the structural stability; in addition, titanium dioxide has an antibacterial effect and can generate a synergistic effect with other components after being modified, so that the performance of the product is improved.

To provide an oil-in-water type emulsified food or the like in which flavor and body peculiar to the oil-in-water type emulsified food containing egg are imparted or enhanced.SOLUTION: The oil-in-water type emulsified food contains (A) arachidonic acid-containing oil and fat, (B) oil and fat other than the arachidonic acid-containing oil and fat, and (C) octenyl succinic acid-treated starch in specific amounts.SELECTED DRAWING: None

This invention relates to nutritional compositions and their uses. Specifically, this invention relates to a nutritional composition comprising: (1) component A consisting of docosahexaenoic acid and arachidonic acid; (2) component B consisting of medium- and long-chain fatty acid triglycerides and 1,3-dioleoyl-2-palmitoyl triglycerides; and (3) component C consisting of choline and taurine. This invention also relates to the use of this nutritional composition for non-therapeutic purposes, including: promoting neurotransmitter expression; improving neuronal structure and function; and improving anxiety. This invention further relates to the use of this nutritional composition in the preparation of products for non-therapeutic purposes, including improving brain development and / or memory and / or improving anxiety. The nutritional composition of this invention can significantly improve brain development and / or memory and / or improve anxiety, which is beneficial for meeting current market demands.

The present invention provides complexes of a specialized pro-resolving mediator (SPM), or a salt, ester, or amide thereof, and a cyclodextrin (CD), wherein the SPM is a hydroxylated, polyunsaturated fatty acid derived from arachidonic acid, eicosapentaenoic acid, docosahexaenoic acid, or docosapentaenoic acid, 20 or 22 carbon atoms in length, with 4, 5 or 6 conjugated double bonds arranged in diene, triene, or tetraene systems or combinations thereof, and related compositions and methods.

The invention discloses a compound melanterite pill specific chromatogram and a construction method and a quality detection method thereof, and belongs to the field of Chinese patent medicine detection. Taking different batches of compound melanterite pills as test articles to prepare a compound melanterite pill test article solution; the method comprises the following steps: taking gallic acid, ginsenoside Rg1, procyanidine B2, cinnamic acid, coumarin, ginsenoside Rh1, cinnamyl alcohol, cinnamaldehyde, arachidonic acid, epicatechin, 2-methoxycinnamic acid, ginsenoside Rb1, ginsenoside Rd, betulinic acid and 5-hydroxymethylfurfural as reference substances to prepare a single reference substance solution; performing chromatographic analysis on the compound melanterite pill test solution and the single reference substance solution, and recording chromatograms; carrying out similarity analysis; and constructing the characteristic chromatogram of the compound melanterite pill according to the chromatogram of the test solution of the compound melanterite pill and the chromatogram of the single reference substance solution in combination with the total ion chromatogram obtained by the high-resolution mass spectrum and the mass spectrum result map of the chemical components. The method can accurately, clearly and objectively evaluate the quality of the compound melanterite pill.

Pet food compositions and methods of using the same are described herein. Such compositions may comprise a ratio of oleic acid to arachidonic acid. The method may include feeding a pet with an effective amount of a pet food composition.

The application provides a mycoplasma hyopneumoniae culture medium capable of significantly improving the strain titer and an application thereof, and belongs to the field of veterinary biological products. The mycoplasma hyopneumoniae culture medium is obtained by adding L-asparagine, myo-inositol, arachidonic acid, urea, histamine, sodium pyruvate, valproic acid, glyceric acid, lysophosphatidic acid, L-citrulline, L-glutamine and L-leucine into a KM2 culture medium containing Bama pig serum. The culture medium can significantly improve the growth rate and viable bacterial titer of the mycoplasma hyopneumoniae under a low serum concentration, and reduces the production cost.

The invention relates to the technical field of grease processing, and discloses a preparation method of sn-2 ARA-rich arachidonic acid grease. The method comprises the following steps: (1) carrying out transesterification on arachidonic acid grease I and fatty acid by taking lipase as a catalyst to obtain an intermediate mixture; the fatty acid is selected from at least two of palmitic acid, oleic acid, linoleic acid, lauric acid, capric acid and caprylic acid; and (2) carrying out purification treatment on the intermediate mixture to obtain the arachidonic acid grease II rich in sn-2 ARA, the relative mass content of the sn-2 ARA in the arachidonic acid grease II rich in sn-2 ARA is not less than 50 wt%. By adopting the method provided by the invention, the arachidonic acid grease rich in sn-2 ARA can be obtained, and the stability of the obtained arachidonic acid grease is better.